Journal of Biological Chemistry
Volume 274, Issue 51, 17 December 1999, Pages 36328-36334
Journal home page for Journal of Biological Chemistry

CELL BIOLOGY AND METABOLISM
The Integrin α9β1 Binds to a Novel Recognition Sequence (SVVYGLR) in the Thrombin-cleaved Amino-terminal Fragment of Osteopontin*

https://doi.org/10.1074/jbc.274.51.36328Get rights and content
Under a Creative Commons license
open access

The integrin α9β1 mediates cell adhesion to tenascin-C and VCAM-1 by binding to sequences distinct from the common integrin-recognition sequence, arginine-glycine-aspartic acid (RGD). A thrombin-cleaved NH2-terminal fragment of osteopontin containing the RGD sequence has recently been shown to also be a ligand for α9β1. In this report, we used site-directed mutagenesis and synthetic peptides to identify the α9β1 recognition sequence in osteopontin. α9-transfected SW480, Chinese hamster ovary, and L-cells adhered to a recombinant NH2-terminal osteopontin fragment in which the RGD site was mutated to RAA (nOPN-RAA). Adhesion was completely inhibited by anti-α9 monoclonal antibody Y9A2, indicating the presence of a non-RGD α9β1recognition sequence within this fragment. Alanine substitution mutagenesis of 13 additional conserved negatively charged amino acid residues in this fragment had no effect on α9β1-mediated adhesion, but adhesion was dramatically inhibited by either alanine substitution or deletion of tyrosine 165. A synthetic peptide, SVVYGLR, corresponding to the sequence surrounding Tyr165, blocked α9β1-mediated adhesion to nOPN-RAA and exposed a ligand-binding-dependent epitope on the integrin β1 subunit on α9-transfected, but not on mock-transfected cells. These results demonstrate that the linear sequence SVVYGLR directly binds to α9β1 and is responsible for α9β1-mediated cell adhesion to the NH2-terminal fragment of osteopontin.

Cited by (0)

*

This work was supported in part by Research Grant for Cardiovascular Diseases 8C-1 from the Ministry of Health and Welfare (to Y. Y.), by a grant from the Tsuchiya Memorial Foundation for Medical Research (to Y. Y.), and by National Institutes of Health Grants HL/AI33259, HL47412, HL53949, and HL56385 (to D. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

FNc

To whom reprint requests and correspondence should be addressed: Dept. of Internal Medicine, National Hiroshima Hospital, 513 Jike, Saijoh Higashi-Hiroshima 739-0041, Japan. Tel.: 81-824-23-2176; Fax: 81-824-22-4675; E-mail: [email protected].